anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Provided is a technology for simulating physiological activity more appropriately. An optimization device according to an embodiment of the present invention is provided with an estimation unit, a first calculation unit, a second calculation unit, and an update unit. The estimation unit estimates a physiological parameter indicating a physiological state by using an estimation model. The first calculation unit calculates a first differential value on the basis of a first estimated value of the physiological parameter in a first time section and an actual measurement value of the physiological parameter in the first time section. The second calculation unit calculates a second differential value on the basis of the first estimated value and a second estimated value that is of the physiological parameter and that is located in a second time section in the past relative to the first time section. The update unit adjusts the estimation model on the basis of the first differential value and the second differential value.
INTRODUCTION: Control of massive hemorrhage (MH) is a life-saving intervention. The use of tourniquets has been studied in prehospital and battlefield settings but not in aquatic environments.
OBJECTIVE: The aim of this research is to assess the control of MH in an aquatic environment by analyzing the usability of two tourniquet models with different adjustment mechanisms: windlass rod versus ratchet.
METHODOLOGY: A pilot simulation study was conducted using a randomized crossover design to assess the control of MH resulting from an upper extremity arterial perforation in an aquatic setting. A sample of 24 trained lifeguards performed two randomized tests: one using a windlass-based Combat Application Tourniquet 7 Gen (T-CAT) and the other using a ratchet-based OMNA Marine Tourniquet (T-OMNA) specifically designed for aquatic use on a training arm for hemorrhage control. The tests were conducted after swimming an approximate distance of 100 meters and the tourniquets were applied while in the water. The following parameters were recorded: time of rescue (rescue phases and tourniquet application), perceived fatigue, and technical actions related to tourniquet skills.
RESULTS: With the T-OMNA, 46% of the lifeguards successfully stopped the MH compared to 21% with the T-CAT (P = .015). The approach swim time was 135 seconds with the T-OMNA and 131 seconds with the T-CAT (P = .42). The total time (swim time plus tourniquet placement) was 174 seconds with the T-OMNA and 177 seconds with the T-CAT (P = .55). The adjustment time (from securing the Velcro to completing the manipulation of the windlass or ratchet) for the T-OMNA was faster than with the T-CAT (six seconds versus 19 seconds; P < .001; effect size [ES] = 0.83). The perceived fatigue was high, with a score of seven out of ten in both tests (P = .46).
CONCLUSIONS: Lifeguards in this study demonstrated the ability to use both tourniquets during aquatic rescues under conditions of fatigue. The tourniquet with the ratcheting-fixation system controlled hemorrhage in less time than the windlass rod-based tourniquet, although achieving complete bleeding control had a low success rate.
(PROBLEMS) To provide a highly safe dietetic composition originating in green coffee beans by which excellent dietetic effects can be obtained and which contributes to the prevention and treatment of life style-related diseases such as diabetes. (MEANS FOR SOLVING PROBLEMS) A dietetic composition  characterized by  comprising, as the active ingredient, a polar solvent extract of defatted green coffee beans. It is preferable that the above-described polar solvent extract is an extract obtained by using water-containing ethanol, still preferably water-containing ethanol having an ethanol concentration of from 40 to 90% (wt/wt). It is preferable that the above-described defatted green coffee beans are those obtained by extracting green coffee beans with N-hexane to thereby separate oily components therefrom. It is recommended to combine the above-described dietetic composition with one or more members selected from among salacia extract, evening primrose extract, sesamine and garcinia. This dietetic composition is usable as a material for foods, drinks, drugs, or skin preparations for external use.
The patients attending hospitals assigned to controlled group received usual care only. The usual care is patients' discussion with the attending physician, and nurse regarding their disease, medications, and subsequent appointments which may take approximately 5 minutes. Two consecutive follow-up visits were scheduled for 3rd month and 6th of initial visit for each patients in similar to interventional group.
BACKGROUND: Lymph node metastases in papillary thyroid cancer (PTC) increase the risk for persistent and recurrent disease. Data on the predictive value of histopathological features of lymph node metastases, however, are inconsistent. The aim of this study was to evaluate the prognostic significance of known and new histopathological features of lymph node metastases in a well-defined cohort of PTC patients with clinically evident lymph node metastases.
METHODS: A total of 1042 lymph node metastases, derived from 129 PTC patients, were reexamined according to a predefined protocol and evaluated for diameter, extranodal extension, cystic changes, necrosis, calcifications, and the proportion of the lymph node taken up by tumor cells. Predictors for a failure to achieve a complete biochemical and structural response to treatment were determined.
RESULTS: The presence of more than 5 lymph node metastases was the only independent predictor for a failure to achieve a complete response to treatment (odds ratio [OR] 3.39 [95% CI, 1.57-7.33], P < .05). Diameter nor any of the other evaluated lymph node features were significantly associated with the response to treatment.
CONCLUSIONS: Detailed reexamination of lymph nodes revealed that only the presence of more than 5 lymph node metastases was an independent predictor of failure to achieve a complete response to treatment. No predictive value was found for other histopathological features, including the diameter of the lymph node metastases. These findings have the potential to improve risk stratification in patients with PTC and clinically evident lymph node metastases.
Umbilical hernia repair, a common Day Surgery procedure in children, is associated with considerable postoperative discomfort. The patient has to meet certain discharge criteria such as tolerating liquids, adequate level of analgesia, etc., prior to being discharged from the day surgery unit.

Currently, both rectus sheath block and local infiltration of the surgical site are used for providing post-operative analgesia for umbilical hernia repair surgery. The local infiltration can only be done at the end of the surgical procedure as it could alter the planes of the surgical field if performed preoperatively. We believe that the analgesia provided prior to the surgical incision will decrease the amount of intraoperative and postoperative opioids used and the subsequent side effects of these medications (5,6). The rectus sheath block, a regional anesthetic technique, offers possible improved pain management following umbilical hernia repair in a recent observational study (1-3,7). We will perform a double-blinded, randomized study to compare the efficacy of rectus sheath block and surgical infiltration in providing postoperative analgesia.
PROBLEM TO BE SOLVED: To allow a pharmaceutical object in any form to attain a tissue processed with laser. SOLUTION: By a delivery device, a specified quantity of pharmaceutical object, solution, or any other substance is delivered to the opening etc., of a TMR path in a human heart or any other region in a human body which is processed with laser, and for preparing such an opening or TMR path or region processed with laser described, a pronged needle having a laser inlet is provided to guide a laser delivery means 102 such as an optical fiber of fiber bundle to near the surface of the heart or any other physical structure. A pharmaceutical inlet receives the pharmaceutical object forwards it to the TMR or other region processed with laser. In an alternative, a pharmaceutical conduit 108 is arranged coaxially in the laser delivery means 102 fundamentally.  As option, a bored tip and/or h-suction device may be provided which will serve locating the device in a position near the tissue to be treated. A piston, i.e., syringe element, is furnished, and the pharmaceutical object is distributed manually or automatically by driving it.
The invention relates to a dental care product, in particular a toothpaste, comprising diamond particles. The diamond particles have sizes in a first size range from 0.3 µm to 2.5 µm, preferably from 0.5 µm to 2.0 µm, most preferably from 0.75 µm to 1.5 µm. The amount of diamond particles having sizes within the first size range is at most 2 % by weight, more preferably at most 1 % by weight, most preferably at most 0.5 % by weight of the product. Moreover, the invention relates to a kit of parts containing a toothbrush (1) and a product as above, wherein the product is a toothpaste. The bristles (2) of the toothbrush (1) may contain abrasive particles (3), such as diamond particles. The bristles (2) may also be capable of at least temporarily retaining diamond particles.
A composition for encapsulation in a soft gelatin shell, the composition comprising ibuprofen, one or more polyoxysorbitan esters, and a base (e.g. potassium hydroxide). The weight ratio of the one or more polyoxysorbitan esters to ibuprofen is from 1.5:1 to 0.0025:1. The weight ratio of the base to ibuprofen is from 1:3 to 1:12. The weight ratio of the one or more polyoxysorbitan esters to base is 0.009:1 to 11:1. The amount of ibuprofen can be from 35% to less than 50% w/w of the composition. The composition can comprise 5% to 20% w/w polyethylene glycol (PEG). The polyethylene glycol can have a molecular weight of up to 1000. The composition can comprise from about 2% to about 10% w/w water. The dose volume of the composition can be from about 0.4 ml to about 1.0 ml. A further aspect of the invention is a soft gel capsule containing a composition comprising ibuprofen and a solvent system. The solvent system comprising polyethylene glycol, one or more polyoxysorbitan esters, potassium hydroxide, and water. The composition can have a weight of 440 to 480 mg and a release rate of ibuprofen of at least 5% in 5 minutes.
During the last two decades, many p38α mitogen-activated protein kinase (p38α MAPK) inhibitors have been developed and tested in preclinical/clinical studies for the treatment of various disorders, especially problems with the origin of inflammation. Previous studies strongly suggest the involvement of the p38α MAPK pathway in the pathogenesis of neurodegenerative disorders. Despite the significant progress made in this field, so far no studies have focused on p38α MAPK inhibitors that have the capability to be used for the treatment of neurodegenerative disorders. In the present review, we evaluated a wide range of well-known p38α MAPK inhibitors (more than 140 small molecules) by measuring key physicochemical parameters to identify those capable of successfully crossing the blood-brain barrier (BBB). As a result, we identify about 50 naturally occurring and synthetic p38α MAPK inhibitors with high potential to cross the BBB, which can be further explored in the future for the treatment of neurodegenerative disorders. In addition, a detailed analysis of the previously released X-ray crystal structure of the inhibitors in the active site of the p38α MAPK enzyme revealed that some residues such as Met109 play a critical role in the occurrence of effective interactions by constructing strong H-bonds. This study can encourage scientists to focus more on the design, production, and biological evaluation of new central nervous system (CNS)-active p38α MAPK inhibitors in the future.
The present invention relates to a mugwort extract and a method for manufacturing the same. More specifically, the mugwort extract contains a useful ingredient having more antioxidant effects than an existing mugwort extract. Therefore, the mugwort extract has excellent ability to reduce active oxygen in a body. The mugwort extract includes a mugwort polysaccharide extract with an immunity enhancement function. Consequently, the mugwort extract can provide effects of autoxidation and immunity enhancement. Moreover, the mugwort extract is obtained without change and destruction of a polyphenol-based compound or a flavonoid-based compound which are included in the mugwort extract. Therefore, the mugwort extract is obtained at an increased yield and the antioxidant effect of the mugwort extract is minimized. Furtheremore, the present invention relates to: the mugwort extract which can be used to promote development of food materials and cosmetic materials by using the mugwort extract containing the useful ingredients of autoxidation and immunity enhancement as active ingredients; and a method for manufacturing the same mugwort extract.
FIELD: medicine, in particular, physiotherapeutic agents used for normalization of disturbed organism functions. SUBSTANCE: agent is obtained by radiation treatment of a solid-state object manufacture of organic dielectric with a resistivity of 10 15 -10 18  Ohm.m by an electron beam. Paraffin or colophony is used as the object. At radiation treatment of a solid-state object the energy of electrons in the beam is selected within 1 to 6 MeV. The absorbed dose of radiation is selected within 10 0 -10 4  Gr. In a particular case radiation treatment of a solid-state object by an electron beam is accomplished in a package made of dielectric film, 20 to 100 μm thick with a resistivity of 10 15 -10 18  Ohm.m. In particular cases the solid-state object is made in the form of a cylinder, 3 to 50 mm in diameter and 2 to 5 mm high, a ball, 1 to 5 mm in diameter, or a cylindrical stick with rounded-off edges, whose diameter makes up 5 to 15 mm, and the length - 20 to 50 mm. EFFECT: reduced cost of the physiotherapeutic agent and expanded field of its application. 8 cl
PURPOSE: We aimed to describe the availability of 31 distinct services and facilities to diagnose, resuscitate, and treat critically unwell obstetric patients.
METHODS: Using a network of anesthesiologists, intensive care clinicians, obstetricians, critical care nurses, and midwives (MaCriCare) from September 2021 to January 2022, we conducted a descriptive international multicenter cross-sectional survey in centers with obstetric units (OUs) in the WHO Europe Region.
RESULTS: The MaCriCare network covers 26 countries and received 1133 responses, corresponding to 2.5 million annual deliveries. The survey identified significant disparities in the availability of the measured 31 services among the OUs, with some services not immediately available and some not available at all. Point-of-care hemoglobin measurements were lacking in 13.8% of OUs. 15.2% of OUs lacked pointof-care lactate measurement, and 11% lacked transfusion services. 23.8% of OUs lacked the ability to administer hypotensive agent infusions in the labor ward. Samebuilding access to cell saver and thromboelastometry was unavailable to 45.5% and 64.4% of OUs, respectively. Access to invasive ventilation was unavailable to 3.4% of OUs, 11.7% were unable to offer same-building access to non-invasive ventilation, and extracorporeal membranous oxygenation was unavailable to 38.3% of the OUs.
CONCLUSION: Critically ill obstetric patients have access to markedly different resources in the WHO Europe Region depending on the OU where they are managed. Consensus on which facilities and services should be universally available is urgently needed.
Prescribing cefprozil in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.

In patients with known or suspected renal impairment (see DOSAGE AND ADMINISTRATION),careful clinical observation and appropriate laboratory studies should be done prior to and during therapy. The total daily dose of cefprozil should be reduced in these patients because high and/or prolonged plasma antibiotic concentrations can occur in such individuals from usual doses. Cephalosporins, including cefprozil, should be given with caution to patients receiving concurrent treatment with potent diuretics since these agents are suspected of adversely affecting renal function.

Prolonged use of cefprozil may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. 

Cefprozil should be prescribed with caution in individuals with a history of gastrointestinal disease particularly colitis.

Positive direct Coombs’ tests have been reported during treatment with cephalosporin antibiotics.
This article discusses the psychological effects of facial palsy (FP) in adults. FP is the abnormal functioning of facial muscles resulting from temporary or permanent damage of the facial nerves. Following facial paralysis, patients can develop motor and psychosocial functioning issues impacting quality of life. In addition, real or perceived judgment in social settings of those with FP increases the risk of low self-esteem, anxiety, and depression. Currently, most available research focuses on surgical patients and suggests a lack of psychological support throughout the affliction. A multidisciplinary approach when treating patients with FP can help improve the patient's quality of life.
The use of ureteral access sheath (UAS) during Retrograde Intrarenal Surgery (RIRS) has been proven effective and reliable in recent years, and publications indicate that it reduces stone-free rates (SFR). Their use is also recommended in the European Urology Guidelines because it improves image quality, reduces intrarenal pressure, and shortens the operation time. For this reason, it has been routinely used in many RIRS cases. In cases where non-vacuum-assisted UAS is used, fragments during stone fragmentation remain in the kidney, and since it is not possible to remove the stones simultaneously, the image may be distorted, and the operation duration may be prolonged. All these may pave the way for postoperative infectious complications. In addition to non-vacuum-assisted UAS, new UASs with flexible ends and vacuum-assisted aspiration have been introduced in the last few years (ClearPetra). Thanks to the aspiration connected to the system, stone fragments can be removed from the body with negative pressure during stone fragmentation. Continuous circulation prevents bleeding during fragmentation and blurring of the visual field due to stone fragments. In addition, since the stone fragments pass through the edges of the sheath without breaking and are removed, a perfect field of view can be provided. Unlike the classical UAS, the tip is flexible, allowing for the safe removal of lower pole stones. Many studies in the literature compare the success and complications of RIRS in cases where conventional UAS was used and not used. In addition, there are publications related to using the newly introduced aspiration access sheath in percutaneous nephrolithotomy. In retrospective publications on using this UAS in RIRS, it has been shown that stone-free rates, operation time, hemoglobin loss, and postoperative infective complications are more successful on the 1st and 30th postoperative days compared to cases where non-vacuum-assisted UAS was used. There is no randomized controlled prospective publication on this subject. This study aims to compare the complications and stone-free rates of RIRS cases where non-vacuum-assisted UAS and new vacuum-assisted UAS were used.
Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/m2 IV over approximately 120 minutes) on Days 1 and 15 of each 28-day cycle.For patients in Arm 2, systemic therapy will be administered on Days 1 and Day 15 of each Cycle on a 28-day cycle basis, compromised of Gemcitabine and Oxaliplatin. If a patient randomized to Arm 2 has intrahepatic progression on any follow-up scan during study treatment, that patient will be eligible to crossover to Arm 1 and commence to pump placement surgery and HAI FUDR treatment. Patients with any extrahepatic progression will not be eligible to utilize the crossover arm. Arm 2 patients will have 28 days from date of the scan showing intrahepatic progression to proceed to the crossover arm.
Participants in this arm had a Copper T380A intrauterine device (CuT380A), also known as the Paragard IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
FIELD: medicine, otorhinolaryngology. SUBSTANCE: it is suggested to apply papain for cleaning cavity against necrotic masses trice daily for 5 d at exposure of 15-20 min at concentration being 20 mg/ml physiological solution. Then, to improve cavitary tissue regeneration it is necessary to apply Curiosin preparation per 1-2 ml/twice daily at exposure of 15-20 min. Treatment is carried out under bacteriological and cytological control and according to the values obtained therapeutic stages should be repeated. EFFECT: higher efficiency and shortened terms of therapy. 2 ex
The invention belongs to the technical field of medicines, and relates to an application of vitamin B2 in preparation of a medicine for treating and preventing fibrotic diseases. The vitamin B2 is vitamin B2 or a pharmaceutically acceptable derivative thereof. The fibrotic diseases comprise pulmonary fibrosis, hepatic fibrosis, renal fibrosis, cardiac fibrosis, endometrial fibrosis, ocular fibrosis, pancreatic fibrosis, spleen fibrosis diseases, bone marrow fibrosis diseases or diseases induced by fibrosis. The vitamin B2 can be combined with one or more pharmaceutically acceptable carriers to form a pharmaceutical composition. Vitamin B2 or a pharmaceutical composition thereof can be used alone or in combination with other drugs. And has the advantages of obvious curative effect, less toxic and side effect and safe use in the aspect of treating the fibrosis diseases.